Brief: Calliditas Partner Everest Medicine's Drug Application Accepted In China
15/11/2022 07:14
Nov 15 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* PARTNER EVEREST MEDICINE'S NEW DRUG APPLICATION FOR
NEFECON IS
ACCEPTED BY CHINA NMPA
Source text for Eikon: ID:nWkr3nfMj5
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations